What are the negatives?, page-5

TFC recently purchase 2 pharmaceutical development and marketing companies in Santalis and Viroxis. There has been no information forthcoming from TFC to help shareholders understand the risks of these acquisition.

Development of drugs can be an expensive enterprise.
How much TFC cash will these companies burn through before making money?
How much TFC management focus and energy will need to be directed at them to the detriment of the core business.